South Korean biotech firm Green Cross has laid a solid foundation for mid-to-long-term expansion in the U.S. market through its intravenous immunoglobulin product Alyglo. Analysts at Heungkuk Securities highlight the company's differentiated competitiveness, projecting robust sales growth and substantial profit contributions. This positions Green Cross to capture a meaningful share of the expanding global IVIG demand.
Alyglo Targets 10% U.S. Market Share
Green Cross outlined its ambitions at a recent Investor Day, setting a mid-to-long-term goal of 10% market share for Alyglo with sales approaching $650 million. Heungkuk Securities analyst Lee Ji-won emphasized that the company has established a strong foothold in the U.S. based on product strengths. For 2025, Alyglo sales are projected at $106 million, equating to 1.6% market share, with high growth anticipated from rising prescriptions and global IVIG demand.
Plasma Supply Chain Secures Long-Term Momentum
A critical enabler is the plasma supply chain from ABO Holdings, acquired by Green Cross last year. The company aims to increase its plasma self-procurement ratio to 80% by 2028, reducing reliance on external sources and supporting scaled production. Heungkuk Securities forecasts a 40% compound annual growth rate for Alyglo sales, with operating margins hitting 30% by 2028, driven by this vertical integration.
Profit Surge and Broader Portfolio Outlook
Alyglo's earnings impact grows sharply. This year, it is expected to generate 250 billion won in sales, comprising 11% of Green Cross's consolidated revenue of 2.25 trillion won and 52% of its 96.1 billion won operating profit. The brokerage views the company's guidance of $200 million in 2027 and $300 million in 2028 as achievable, with profitability accelerating as revenue share expands.
Synergies with Subsidiaries Enhance Value
Momentum builds from Alyglo's U.S. prescription growth coinciding with recoveries at key subsidiaries like GC Cell. Development of a subcutaneous immunoglobulin (SCIG) variant promises further portfolio diversification. Heungkuk Securities upholds a "Buy" rating with a 190,000 won target price, signaling confidence in sustained profit expansion amid a tightening global supply for plasma-derived therapies.
